^
    4d
    Cytological, Immunocytochemical and Molecular Findings of Extraskeletal Round Cell Sarcomas in Paediatric Patients. (PubMed, Acta Cytol)
    Key messages Round cell sarcomas share many morphological similarities, so the differential diagnosis can be broad; however, subtle differences between tumours can aid the final diagnosis. Nevertheless, most round cell sarcomas require molecular studies for accurate classification, and cytological specimens are usually high quality material for such ancillary techniques.
    Review • Journal
    |
    BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1)
    5d
    Adult liver rhabdomyosarcoma complicated with sarcomatoid carcinoma: A case report. (PubMed, World J Gastrointest Oncol)
    By sharing the diagnosis and treatment process of this patient and reviewing the relevant literature, we aim to help clinicians enhance their understanding of two rare diseases, namely pleomorphic RMS and sarcomatoid carcinoma of the liver.
    Journal • IO biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • AFP (Alpha-fetoprotein)
    |
    MET amplification
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine
    5d
    PROSARC-1: Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=110, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    PROSARC-2: Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma. (clinicaltrials.gov)
    P2, N=40, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    7d
    Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE) (clinicaltrials.gov)
    P1, N=18, Recruiting, Children's National Research Institute | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Jan 2026
    Enrollment open • Trial initiation date
    |
    cyclophosphamide
    8d
    Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma (clinicaltrials.gov)
    P2, N=59, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Feb 2025
    Trial completion • Trial completion date
    |
    gemcitabine • albumin-bound paclitaxel
    8d
    A scientometric and comparative study of rhabdomyosarcoma research by pediatricians and stomatologists. (PubMed, J Dent Sci)
    Cancer chemotherapy mainly vincristine, dactinomycin, and cyclophosphamide, surgery, radiotherapy, and brachytherapy were the common keywords of treatment. The more common keywords such as age, facial neoplasms, mouth neoplasms, orbital neoplasms, gingiva, mandible, DNA-binding proteins, gene silencing, and Rh30 cell line were reported by stomatologists. This study is the first comprehensive report of the scientometric characteristics of RMS publications by pediatricians and stomatologists, highlighting the need for increased awareness among clinicians to avoid diagnostic delays and ensure timely treatment.
    Journal
    |
    FOXO1 (Forkhead box O1) • PAX3 (Paired Box 3)
    |
    cyclophosphamide • vincristine • dactinomycin
    8d
    Case of primary digital embryonal rhabdomyosarcoma in a cat. (PubMed, Can Vet J)
    Suitably, this case report provides valuable insight into the management of similar cases in cats. Key clinical message: This first reported case of digital RMS in a cat highlights the importance of studying the clinical presentation and treatment of RMS in feline patients.
    Journal
    |
    VIM (Vimentin) • MYOD1 (Myogenic Differentiation 1)
    8d
    Clinical management and therapeutic development for the rare disease rhabdomyosarcoma. (PubMed, J Cancer)
    Targeted therapy that tailors treatment plans to the individual patient may provide additional benefits for RMS patients. This review describes the frequent genetic mutations observed in RMS patients and drug development based on these mutations shall provide direction to develop targeted therapy leading to effective personalized treatment for RMS patients.
    Review • Journal
    |
    FOXO1 (Forkhead box O1)
    10d
    PEPN2112: Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=31, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Mar 2026
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • WT1 (WT1 Transcription Factor) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • POLD1 (DNA Polymerase Delta 1) • FOXO1 (Forkhead box O1) • XRCC2 (X-Ray Repair Cross Complementing 2) • ATF1 (Activating Transcription Factor 1) • PAX3 (Paired Box 3)
    |
    elimusertib (BAY 1895344)
    12d
    A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma (clinicaltrials.gov)
    P2, N=106, Not yet recruiting, Fudan University
    New P2 trial
    |
    Focus V (anlotinib) • cyclophosphamide
    14d
    Alveolar rhabdomyosarcoma with multiple bone marrow metastases: a case report. (PubMed, BJR Case Rep)
    Contrast-enhanced CT/MRI revealed a mass with marked heterogeneous enhancement and an enhancing pseudocapsule, while pathological examination confirmed the diagnosis through immunohistochemical markers (MyoD1 (+), Myogenin (+), Desmin (+)). This case highlights the aggressive nature of ARMS and the importance of characteristic imaging findings.
    Journal
    |
    MYOD1 (Myogenic Differentiation 1)